Ractigen Therapeutics Overview

  • Year Founded
  • 2016

Year Founded

  • Status
  • Private

  • Employees
  • 50

Employees

  • Latest Deal Type
  • Series A1

  • Latest Deal Amount
  • $31.4M

  • Investors
  • 9

Ractigen Therapeutics General Information

Description

Developer of medicines designed for the RNA activation (RNAa) field. The company's products mainly focus on treating diseases that arise from inadequate gene expression with several innovative patents, and the key therapeutic areas include central nervous system (CNS) diseases, tumors, liver diseases, ophthalmic diseases, etc., providing customers with innovative and efficient products.

Contact Information

Website
www.ractigen.com
Formerly Known As
Nantong Sino-US Ruikang Biotechnology Co., Ltd., Sino-US Ruikang Pharmaceutical Technology (Nantong) Co., Ltd.
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Bldg.18, Rudong Life & Health Industry Park
  • No. 888 Zhujiang Rd, Rudong County
  • Nantong, Jiangsu 226400
  • China
+86 0512
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Life Sciences, Oncology
Corporate Office
  • Bldg.18, Rudong Life & Health Industry Park
  • No. 888 Zhujiang Rd, Rudong County
  • Nantong, Jiangsu 226400
  • China
+86 0512

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Ractigen Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Later Stage VC (Series A1) 27-Jan-2022 $31.4M Completed Pre-Clinical Trials
2. Early Stage VC (Series A) 11-Feb-2021 Completed Pre-Clinical Trials
1. Seed Round 25-Oct-2016 $7.46M $7.46M Completed Pre-Clinical Trials
To view Ractigen Therapeutics’s complete valuation and funding history, request access »

Ractigen Therapeutics Patents

  • 59

    Total Documents Applications and Grants

  • Total Patents Families

  • Granted

  • 40

    Pending

  • Expiring in next 12 mo

Ractigen Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2023300752-A1 Oligonucleotide delivery enhancing compounds, pharmaceutical compositions and methods using the same Pending 27-Jun-2022
EP-4466359-A1 Oligonucleotide modulators activating utrophin expression Pending 20-Jan-2022
AU-2023209973-A1 Oligonucleotide modulators activating utrophin expression Pending 20-Jan-2022
US-20250101421-A1 Oligonucleotide modulators activating utrophin expression Pending 20-Jan-2022
AU-2022308123-A1 Oligonucleotide-based delivery vehicle for oligonucleotides agents and methods of use thereof Pending 07-Jul-2021 C12N15/1137
To view Ractigen Therapeutics’s complete patent history, request access »

Ractigen Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Ractigen Therapeutics Investors (9)

Investor Name Investor Type Holding Investor Since Participating Rounds
China-Singapore Suzhou Industrial Park Development Group Corporation Minority
Eisai Corporate Venture Capital Minority
HM Capital Venture Capital Minority
Ling Cheng Ventures Venture Capital Minority
SDIC Venture Capital Venture Capital Minority
You’re viewing 5 of 9 investors. Get the full list »

Ready to get started?

Request a free trial

Ractigen Therapeutics FAQs

  • When was Ractigen Therapeutics founded?

    Ractigen Therapeutics was founded in 2016.

  • Where is Ractigen Therapeutics headquartered?

    Ractigen Therapeutics is headquartered in Nantong, China.

  • What is the size of Ractigen Therapeutics?

    Ractigen Therapeutics has 50 total employees.

  • What industry is Ractigen Therapeutics in?

    Ractigen Therapeutics’s primary industry is Drug Discovery.

  • Is Ractigen Therapeutics a private or public company?

    Ractigen Therapeutics is a Private company.

  • What is Ractigen Therapeutics’s current revenue?

    The current revenue for Ractigen Therapeutics is .

  • How much funding has Ractigen Therapeutics raised over time?

    Ractigen Therapeutics has raised $54M.

  • Who are Ractigen Therapeutics’s investors?

    China-Singapore Suzhou Industrial Park Development Group, Eisai, HM Capital, Ling Cheng Ventures, and SDIC Venture Capital are 5 of 9 investors who have invested in Ractigen Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »